Regeneron Pharmaceuticals Posts Higher Revenue in 4Q
06 February 2020 - 11:13PM
Dow Jones News
By Amber Burton
Regeneron Pharmaceuticals Inc. (REGN) reported roughly 13%
higher revenue and beat expectations for adjusted earnings in the
latest quarter.
The biotech company said its fourth-quarter earnings were $792
million, or $6.93 a share, compared with $820 million, or $7.15 a
share a year earlier.
Adjusted earnings were $7.50 a share. Analysts polled by FactSet
were expecting adjusted earnings of $6.93 a share.
Total revenue was $2.17 billion, up from $1.93 billion a year
earlier.
Analysts were expecting revenue of $2.11 billion.
Write to Amber Burton at amber.burton@wsj.com
(END) Dow Jones Newswires
February 06, 2020 06:58 ET (11:58 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024